Characteristics of measurable residual disease assessment in myeloma: a review of clinical trials from 2015–2020

• Oliver Van Oekelen,
• Nicole Birrer,
• William Wesson,
• Vincent L. Galate,
• Edward R. Scheffer Cliff,
• Aaron M. Goodman,
• Al-Ola Abdallah,
• Rajshekhar Chakraborty,
• Vinay Prasad,
• Ghulam Rehman Mohyuddin

Affiliations

Oliver Van Oekelen

Department of Internal Medicine, Icahn School of Medicine at Mount Sinai, Mount Sinai Beth Israel, Department of Internal Medicine

Nicole Birrer

University of Utah, Huntsman Cancer Center, Division of Hematology

William Wesson

University of Kansas, University of Kansas School of Medicine

Vincent L. Galate

University of Kansas, University of Kansas School of Medicine

Edward R. Scheffer Cliff

Program on Regulation, Therapeutics and Law, Brigham and Women’s Hospital, Harvard Medical School

Aaron M. Goodman

Division of Blood and Marrow Transplantation, University of California San Diego

Al-Ola Abdallah

University of Kansas, University of Kansas School of Medicine

Rajshekhar Chakraborty

Department of Hematology, Columbia University

Vinay Prasad

Division of Hematology/Oncology, Department of Medicine, University of California San Francisco

Ghulam Rehman Mohyuddin

University of Utah, Huntsman Cancer Center, Division of Hematology